scholarly journals Monitoring the reduction and maintenance of periprosthetic bone tissue in cementless primary hip endoprosthesis with alendronate therapy

2021 ◽  
Vol 13 (2) ◽  
pp. 1-9
Author(s):  
Ilir Shabani ◽  
Milan Samardziski ◽  
Viktor Kamnar ◽  
Neron Popovski ◽  
Antonio Gavrilovski ◽  
...  
Keyword(s):  
Bone Tissue ◽  
Bone Mineral ◽  
Mineral Content ◽  
Bone Mineralization ◽  
Mineral Density ◽  
Periprosthetic Bone ◽  
Hip Endoprosthesis ◽  
X Ray ◽  
Bone Mass Loss ◽  
Bone Maintenance

Loss of periprosthetic bone tissue in primary hip endoprostheses is common in clinical practice. This loss can be progressive and in extreme conditions can jeopardize the longevity of the prosthesis. In order to monitor the function of Alendronate therapy for bone maintenance, the study included 50 patients with implanted total cement-free hip endoprosthesis (TPH). The first group of 25 patients received Alendronate, calcium and vitamin D3 orally postoperatively. The second group of 25 patients were examined postoperatively without therapy. Patients were followed by radiographic and dual-energy X-ray absorptiometry (DXA) at 6 and 12 months. The study showed that in patients with TPH there was a difference in the X-ray findings as well as occurrence of osteolysis in certain Gruen zones, which was confirmed by changes in the state of bone mineral density (BMD) and bone mineral content (BMC) in the interval between 6 and 12 months using the DXA method. Alendronate therapy after TPH implantation allows reduction of periprosthetic bone mass loss, maintenance of bone mineralization and implant hardening.

scholarly journals Influence of alendronate therapy on the results of densitometric examination after implantation of total hip endoprosthesis

2021 ◽  
Vol 13 (1) ◽  
pp. 32-38
Author(s):  
Ilir Shabani ◽  
Antonio Gavrilovski ◽  
Vilijam Velkovski ◽  
Nenad Atanasov ◽  
Shaban Memeti ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Loss ◽  
Bone Mass ◽  
Bone Mineral ◽  
Mineral Content ◽  
Mineral Density ◽  
Periprosthetic Bone ◽  
Hip Endoprosthesis ◽  
Periprosthetic Bone Loss ◽  
Post Implantation

The development of aloarthroplasty of the hip is continuously rising. After implantation of a total cement-free hip endoprosthesis, often there is a periprosthetic femoral bone loss. Alendronate has been shown to be a potent inhibitor of bone resorption activity; it inhibits osteoclastic bone resorption, increases bone mass, and plays a significant role in post-implantation stabilization of the femur. The aim of this study was to determine the effect of alendronate on osteointegration of hip endoprosthesis.Material and methods: The study analyzed 10 patients operated on with implantation of a total cement-free hip endoprosthesis (THP). The included patients were examined by a radiographic method at 6 and 12 months and DXA method at 6 and 12 months. Results: The study showed differences in the values of bone mineral density and bone mineral content in the interval between 6 and 12 months in patients undergoing THP, and hence we can conclude that alendronate therapy after THP implantation reduced periprosthetic loss of bone mass and implant stiffening. Alendronate is a proven inhibitor of periprosthetic bone loss that occurs after prirmary impantation of a total cement-free hip endoprosthesis.

scholarly journals Explore Upper Limits of Bone Mineral Content And Density In Humans: A Study On Japanese Collegiate Sumo Wrestlers

2021 ◽  
Author(s):  
Taishi Midorikawa ◽  
Suguru Torii ◽  
Megumi Ohta ◽  
Shizuo Sakamoto
Keyword(s):  
Body Weight ◽  
Bone Mineral Content ◽  
Bone Mineral ◽  
Fat Mass ◽  
Mineral Content ◽  
Mineral Density ◽  
Tissue Mass ◽  
X Ray ◽  
Upper Limit ◽  
Upper Limits

Abstract The purpose of this study was to explore the upper limit of total bone mineral content (BMC, kg) and bone mineral density (BMD, g/cm2) in humans by estimating body composition of Sumo wrestlers. A total of 54 male college Sumo wrestlers were recruited for the study and assigned to 2 groups according to body weight (middleweight, 85-115 kg, n = 23 and heavyweight, >115 kg, n = 31). BMC, BMD, fat mass and lean soft tissue mass (LSTM) were measured using dual-energy X-ray absorptiometry (DXA) for the total and appendicular regions. Heavyweight Sumo wrestlers had significantly greater body weight, fat mass, and LSTM compared to middleweight Sumo wrestlers. Mean total BMC was significantly larger in heavyweight than middleweight Sumo wrestlers, respectively (The highest value was 4.16 kg.). Total BMD was significantly higher in heavyweight compared to middleweight Sumo wrestlers (The highest value was 1.59 g/cm2.), and was significantly correlated with body weight, but not with fat mass and LSTM. Based on the present and previous studies, the upper limit of total BMC and BMD in humans with 150 kg bodyweight might be around 5.0 kg and 1.60 g/cm2.

Evaluation of periprosthetic bone using dual-energy X-ray absorptiometry: Precision of the method and effect of operation on bone mineral density

2009 ◽  
Vol 11 (10) ◽  
pp. 1526-1530 ◽  
Author(s):  
Heikki Kröger ◽  
Hannu Miettinen ◽  
Ilkka Arnala ◽  
Eila Koski ◽  
Neil Rushton ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Dual Energy ◽  
Mineral Density ◽  
Periprosthetic Bone ◽  
X Ray

Effect of single neonatal vitamin D3 treatment (hormonal imprinting) on the bone mineralization of adult non-treated and dexamethasone treated rats

1998 ◽  
Vol 17 (8) ◽  
pp. 424-429 ◽  
Author(s):  
Cs Karabélyos ◽  
Cs Horváth ◽  
I Holló ◽  
G Csaba
Keyword(s):  
Vitamin D ◽  
Body Weight ◽  
Bone Mineral ◽  
Mineral Content ◽  
Bone Mineralization ◽  
The Body ◽  
Mineral Density ◽  
Hormonal Imprinting ◽  
Old Rats ◽  
Old Females

Hormonal imprinting (the first encounter between the hormone and receptor after birth) is needed for the normal development of receptor. Presence of the appropriate hormone in excess, or its absence, as well as presence of hormone-like molecules able to bind to the maturing receptor in this time, can cause faulty imprinting. In this experiment the effect of neonatal treatment with a single dose of 0.05 mg cholecalciferol (vitamin D3) was studied by bone densitometry. The treatment caused significant decrease of body weight in 3-month old females and also significant reduction of bone mineral density (BMD) and bone mineral content (BMC) in males. Dexamethasone treatment of 3-month old rats for 10 days increased BMD in males and BMC in females without affecting body weight. The double treatment (vitamin D neonatally and dexamethasone when adult) decreased the body weight of both sexes and increased BMD in males, and BMC, BMD/bw and BMC/bw in both sexes, related to the control or the only vitamin D treated groups. Considering the hormonal imprinting effect of neonatal vitamin D treatment at glucocorticoid receptorial level in other experiments, similar effects also can be supposed for vitamin D itself, manifested in the changes of bone mineralization.

Sign in / Sign up

Export Citation Format

Share Document